Suppr超能文献

2009 年至 2019 年澳大利亚男同性恋、双性恋和其他与男性发生性关系的男性中丙型肝炎的发病率。

The Incidence of Hepatitis C Among Gay, Bisexual, and Other Men Who Have Sex With Men in Australia, 2009-2019.

机构信息

Disease Elimination Program, Burnet Institute, Melbourne, Australia.

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

出版信息

Clin Infect Dis. 2022 May 30;74(10):1804-1811. doi: 10.1093/cid/ciab720.

Abstract

BACKGROUND

Hepatitis C virus (HCV) infection has been reported among gay, bisexual, and other men who have sex with men (GBM) globally including GBM with human immunodeficiency virus (HIV) and HIV-negative GBM, particularly those using HIV preexposure prophylaxis (PrEP). In Australia, HCV direct-acting antiviral treatment (DAA) was government-funded from 2016. Large implementation studies of PrEP also began in 2016. We examined HCV incidence among GBM to assess whether HCV incidence has changed since 2015.

METHODS

Data were drawn from the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance. We included GBM who tested HCV antibody negative at their first test and had ≥1 subsequent test. Generalized linear modeling (Poisson distribution) was used to examine HCV incidence from 2009 to 2019 stratified by HIV status, and among HIV-negative GBM prescribed PrEP from 2016 to 2019.

RESULTS

Among 6744 GBM with HIV, HCV incidence was 1.03 per 100 person-years (PY). Incidence declined by 78% in 2019 compared to 2015 (incidence rate ratio [IRR], 0.22 [95% confidence interval {CI}: .09-.55]). Among 20 590 HIV-negative GBM, HCV incidence was 0.20/100 PY, with no significant change over time. Among 11 661 HIV-negative GBM prescribed PrEP, HCV incidence was 0.29/100 PY. Compared to 2016, incidence among GBM prescribed PrEP declined by 80% in 2019 (IRR, 0.20 [95% CI: .06-.64]).

CONCLUSIONS

HCV incidence among GBM living with HIV declined following DAA availability. There was no observed change in HCV incidence among HIV-negative GBM overall. Among GBM prescribed PrEP, incidence declined since the early years of PrEP implementation in Australia. Australia is on track to eliminate HCV among GBM before global 2030 targets.

摘要

背景

全球范围内,包括感染人类免疫缺陷病毒(HIV)和 HIV 阴性的男同性恋、双性恋和其他与男性发生性关系的男性(GBM)在内的 GBM 中均有丙型肝炎病毒(HCV)感染的报告,特别是那些使用 HIV 暴露前预防(PrEP)的人群。在澳大利亚,自 2016 年起,HCV 直接作用抗病毒治疗(DAA)由政府出资。大规模的 PrEP 实施研究也于 2016 年开始。我们检测了 GBM 中的 HCV 发病率,以评估自 2015 年以来 HCV 发病率是否发生了变化。

方法

数据来自澳大利亚合作加强监测哨点。我们纳入了首次检测 HCV 抗体阴性且至少有 1 次后续检测的 GBM。采用广义线性模型(泊松分布)对 2009 年至 2019 年按 HIV 状态分层的 HCV 发病率以及 2016 年至 2019 年 HIV 阴性的 GBM 服用 PrEP 后的 HCV 发病率进行了检测。

结果

在 6744 名感染 HIV 的 GBM 中,HCV 发病率为每 100 人年 1.03 例(95%置信区间[CI]:0.09-0.55)。与 2015 年相比,2019 年 HCV 发病率下降了 78%(发病率比[IRR],0.22 [95%CI:0.09-0.55])。在 20590 名 HIV 阴性的 GBM 中,HCV 发病率为 0.20/100PY,且无时间变化。在 11661 名 HIV 阴性的 GBM 中,接受 PrEP 治疗的 HCV 发病率为 0.29/100PY。与 2016 年相比,2019 年接受 PrEP 治疗的 GBM 的发病率下降了 80%(IRR,0.20 [95%CI:0.06-0.64])。

结论

随着 DAA 的普及,HIV 合并感染的 GBM 中的 HCV 发病率下降。总体而言,HIV 阴性的 GBM 中 HCV 发病率没有观察到变化。在接受 PrEP 治疗的 GBM 中,自澳大利亚开始实施 PrEP 的早期以来,发病率有所下降。澳大利亚有望在 2030 年全球目标之前消除 GBM 中的 HCV。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验